Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial

<strong>Background</strong> Vaccination of children and young people against SARS-CoV-2 is recommended in some countries. Scarce data have been published on immune responses induced by COVID-19 vaccines in people younger than 18 years compared with the same data that are available in adu...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän:	Li, G, Cappuccini, F, Marchevsky, NG, Aley, PK, Aley, R, Anslow, R, Bibi, S, Cathie, K, Clutterbuck, E, Faust, SN, Feng, S, Heath, PT, Kerridge, S, Lelliott, A, Mujadidi, Y, Ng, KF, Rhead, S, Roberts, H, Robinson, H, Roderick, MR, Singh, N, Smith, D, Snape, MD, Song, R, Tang, K, Yao, A, Liu, X, Lambe, T, Pollard, AJ
Övriga upphovsmän:	COV006 study team
Materialtyp:	Journal article
Språk:	English
Publicerad:	Elsevier 2022

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial

Liknande verk